30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective-Reference-Cited by-同舟云学术

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Published:2021-12 Issue:1 Volume:40 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Sharma Amit^ORCID,Schmidt-Wolf Ingo G. H.

Abstract

AbstractEmerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1186/s13046-021-02184-2.pdf

Reference10 articles.

1. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49. https://doi.org/10.1084/jem.174.1.139.

2. Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235:9291–303. https://doi.org/10.1002/jcp.29827.

3. Dalla Pietà A, et al. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021;9. https://doi.org/10.1136/jitc-2021-002475.

4. Wang S, et al. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 2020;20:601–7. https://doi.org/10.1080/14712598.2020.1728250.

5. Introna M, Correnti F. Innovative clinical perspectives for CIK cells in cancer patients. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19020358.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma;Molecular Cancer;2024-08-09

2. Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy;Cell Reports Methods;2024-08

3. Editorial: Cancer immunotherapies for hematologic malignancies - NK/CIK/CAR-T perspective;Frontiers in Immunology;2024-06-18

4. Efficacy of Chemoimmunotherapy versus Chemotherapy for Gastric Cancer: A Meta-Analysis of Survival Outcomes;Current Medicinal Chemistry;2024-06

5. Enhanced cellular therapy: revolutionizing adoptive cellular therapy;Experimental Hematology & Oncology;2024-04-25